Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer

“…The cell lines used in the present study (Table I) were established at the Cancer Institute of the University of Pittsburgh (Pittsburgh, PA, USA) (23). As described previously (15,24), the cells were cultured in a humidified atmosphere of 5% CO 2 /95% air at 37˚C and were fed 2-3 times per week with Dulbecco's Modified Eagle's Medium (DMEM; Life Technologies, GmbH, Darmstadt, Germany) with low glucose, 10% fetal calf serum (Life Technologies, GmbH), 1% penicillin/streptomycin (Life Technologies, GmbH) and 1% L-glutamine (Biochrom KG, Berlin, Germany).…”

111In-Cetuximab-F(ab′)2 SPECT and 18F-FDG PET for Prediction and Response Monitoring of Combined-Modality Treatment of Human Head and Neck Carcinomas in a Mouse Model

“…However, in a phase II study by Wierzbicki et al, it was shown that even without detectable EGFR, cetuximab as a monotherapy for colorectal carcinomas could be clinically effective and recently, an inverse relationship between EGFR expression and response was noted by Hartmann et al (8,9). Nuclear medicine imaging advances on biopsy/single cell-dependent techniques because it allows the noninvasive assessment of the EGFR in the intact tumor, accounting for intratumoral variables such as vasculature, blood supply, and interstitial fluid pressure.…”

Unknown primary of the head and neck: A long-term follow-up

“…Hartman published recently the efficacy of anti-epidermal growth factor receptor (EGFR) treatment depending on lower EGFR expression in head and neck cancer cell lines (Hartmann et al, 2014). The impact of immunotherapy in patients with head and neck CUP has not been described in the literature, and might be of interest for further investigation.…”